• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by IDEAYA Biosciences Inc.

    2/18/25 4:36:42 PM ET
    $IDYA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IDYA alert in real time by email
    S-8 1 idya-20250218.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on February 18, 2025

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

    IDEAYA Biosciences, Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

     

    Delaware

     

    47-4268251

    (State or other jurisdiction of

    incorporation or organization)

     

     

     

    (I.R.S. Employer

    Identification Number)

     

     

     

     

    5000 Shoreline Court, Suite 300

    South San Francisco, California

     

    94080

    (Address of Principal Executive Offices)

     

    (Zip Code)

    2019 Incentive Award Plan

    2019 Employee Stock Purchase Plan

    (Full Title of the Plan)

    Yujiro Hata

    President and Chief Executive Officer

    IDEAYA Biosciences, Inc.

    5000 Shoreline Court, Suite 300

    South San Francisco, California 94080

    (650) 443-6209

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

    Mark V. Roeder, Esq.

    Benjamin A. Potter, Esq.

    Latham & Watkins LLP

    140 Scott Drive

    Menlo Park, California 94025

    Telephone: (650) 328-4600

    Facsimile: (650) 463-2600

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,”

     


     

    “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

     

     

     

    Large accelerated filer

     

    ☒

     

    Accelerated filer

     

    ☐

     

     

     

     

    Non-accelerated filer

     

    ☐

     

    Smaller reporting company

     

     

    ☐

     

     

     

     

     

     

     

     

    Emerging growth company

     

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     


     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed with the Securities and Exchange Commission (the “Commission”) for the purpose of registering an additional 4,325,175 shares of common stock, par value $0.0001 per share (“common stock”), of IDEAYA Biosciences, Inc. (the “Registrant”) issuable under the following employee benefit plans for which registration statements of the Registrant on Form S-8 (File Nos. 333-231784, 333-237362, 333-254617, 333-263657, 333-270334, 333-277189) are effective: (i) the IDEAYA Biosciences, Inc. 2019 Incentive Award Plan which, as a result of the operation of an automatic annual increase provision therein, added 3,460,140 shares of common stock and (ii) the IDEAYA Biosciences, Inc. Employee Stock Purchase Plan which, as a result of the operation of an automatic annual increase provision therein, added 865,035 shares of common stock.

     

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”).

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    In this registration statement, IDEAYA Biosciences, Inc. is sometimes referred to as “Registrant,” “we,” “us” or “our.”

     

    INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENTS ON FORM S-8

     

    Pursuant to Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the SEC on May 28, 2019 (File No. 333-231784), March 24, 2020 (File No. 333-237362), March 23, 2021 (File No. 333-254617), March 17, 2022 (File No. 333-263657), March 7, 2023 (File No. 333-270334) and February 20, 2024 (File No. 333-277189) are incorporated by reference herein; except for Item 8, which is being updated by this Registration Statement.

    Item 3. Incorporation of Documents by Reference.

    The SEC allows us to incorporate by reference the information we file with them, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this registration statement, and later information filed with the SEC will update and supersede this information. We hereby incorporate by reference into this registration statement the following documents previously filed with the SEC:

     

    (a)

    Our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 18, 2025;

     

     

    (b)

    Our Current Reports on Form 8-K filed with the SEC on February 10, 2025;

     

     

    (c)

    The information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K from our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 19, 2024; and

     

     


     

     

    (d)

    The description of the Registrant’s common stock contained in the Registrant’s “Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934” filed as Exhibit 4.3 to our Annual Report on Form 10-K for the year ended December 31, 2024 and any amendments or reports filed for the purpose of updating such description.

     

    All documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to the registration statement which indicates that all of the shares of common stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be a part hereof from the date of the filing of such documents; except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under current Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such form that relate to such items, that is not deemed filed under such provisions. For the purposes of this registration statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

    Under no circumstances will any information filed under current Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such form that relate to such items, be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

    Item 8. Exhibits.

    Exhibit Index

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Exhibit

    Number

     

    Exhibit Description

     

    Incorporated by Reference

     

     

    Filed

    Herewith

     

     

     

    Form

     

    Date

     

     

    Number

     

     

     

     

     

     

     

     

    4.1

     

    Amended and Restated Certificate of Incorporation.

     

    8-K

     

     

    5-28-19

     

     

     

    3.1

     

     

     

     

     

     

     

     

     

     

     

    4.2

     

    Amended and Restated Bylaws.

     

    8-K

     

     

    5-28-19

     

     

     

    3.2

     

     

     

     

     

     

     

     

     

     

     

    4.3

     

    Form of Common Stock Certificate.

     

    S-1/A

     

     

    5-13-19

     

     

     

    4.2

     

     

     

     

     

     

     

     

     

     

     

    5.1

     

    Opinion of Latham & Watkins LLP.

     

     

     

     

     

     

     

     

     

     

     

     

    X

     

     

     

     

     

     

     

    23.1

     

    Consent of Independent Registered Public Accounting Firm.

     

     

     

     

     

     

     

     

     

     

     

     

    X

     

     

     

     

     

     

     

    23.2

     

    Consent of Latham & Watkins LLP (included in Exhibit 5.1).

     

     

     

     

     

     

     

     

     

     

     

     

    X

     

     

     

     

     

     

     

    24.1

     

    Power of Attorney. Reference is made to the signature page to the Registration Statement.

     

     

     

     

     

     

     

     

     

     

     

     

    X

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.1(a)#

     

    2019 Incentive Award Plan.

     

    S-8

     

     

    5-28-19

     

     

     

    99.2

    (a)

     

     

     

     

     

     

     

     

     

     

    99.1(b)#

     

    Form of Stock Option Grant Notice and Stock Option Agreement under the 2019 Incentive Award Plan.

     

    S-1

     

     

    5-13-19

     

     

     

    10.5

    (b)

     

     

     

     

     

     

     

     

     

     

    99.1(c)#

     

    Form of Restricted Stock Award Agreement under the 2019 Incentive Award Plan.

     

    S-1

     

     

    5-13-19

     

     

     

    10.5

    (c)

     

     

     

     

     

     

     

     

     

     

    99.1(d)#

     

    Form of Restricted Stock Unit Award Grant Notice under the 2019 Incentive Award Plan.

     

    S-1

     

     

    5-13-19

     

     

     

    10.5

    (d)

     

     

     

     

     

     

     

     

     

     

    99.2#

     

    2019 Employee Stock Purchase Plan.

     

    S-8

     

     

    5-28-19

     

     

     

    99.3

     

     

     

     

     

     


     

     

     

     

     

    107

     

    Filing Fee Table

     

     

     

     

     

     

     

     

     

     

     

     

    X

     

     

     

     

    #

    Indicates management contract or compensatory plan.

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in South San Francisco, California, on this 18th day of February, 2025.

     

     

     

    IDEAYA Biosciences, Inc.

     

     

    By:

     

    /s/ Yujiro Hata

     

     

    Yujiro Hata

     

     

    President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Yujiro Hata and Andres Ruiz Briseno, and each of them acting individually, as his true and lawful attorneys-in-fact and agents, each with full power of substitution, for him in any and all capacities, to sign any and all amendments to this Registration Statement, including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule 462(b) increasing the number of securities for which registration is sought, and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

     

     

     

     

    Signature

     

    Title

     

    Date

     

     

     

    /s/ Yujiro Hata

    Yujiro Hata

     

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

     

    February 18, 2025

     

     

     

    /s/ Andres Ruiz Briseno

    Andres Ruiz Briseno.

     

    SVP, Head of Finance and Investor Relations

    (Principal Financial and Accounting Officer)

     

    February 18, 2025

     

     

     

    /s/ Terry Rosen, Ph.D.

    Terry Rosen, Ph.D.

     

    Chairman of the Board of Directors

     

    February 18, 2025

     

     

     

    /s/ Garret Hampton, Ph.D.

    Garret Hampton, Ph.D.

     

    Director

     

    February 18, 2025

     

     

     

    /s/ Susan L. Kelley, M.D.

    Susan L. Kelley, M.D.

     

    Director

     

    February 18, 2025

     

     

     

    /s/ Catherine Mackey, Ph.D.

    Catherine Mackey, Ph.D.

     

    Director

     

    February 18, 2025

     

     

     

    /s/ Scott Morrison

    Director

    February 18, 2025

    Scott Morrison

     


     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    /s/ Jeffrey Stein, Ph.D.

     

    Director

     

    February 18, 2025

    Jeffrey Stein, Ph.D.

     

     

     

     

     

     

     

    /s/ Wendy Yarno

     

    Director

     

    February 18, 2025

    Wendy Yarno

     

     

     


    Get the next $IDYA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IDYA

    DatePrice TargetRatingAnalyst
    11/18/2024$51.00Overweight
    Stephens
    11/5/2024$27.00Outperform → Market Perform
    Leerink Partners
    10/24/2024$50.00Buy
    UBS
    10/15/2024Overweight
    Cantor Fitzgerald
    7/8/2024$50.00Outperform
    Mizuho
    3/8/2024$55.00Buy
    BTIG Research
    8/8/2023$33.00Outperform
    SVB Securities
    5/24/2023$32.00Buy
    Goldman
    More analyst ratings

    $IDYA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

      ~$1.05 billion of cash, cash equivalents and marketable securities as of March 31, 2025, and an updated cash runway guidance into 2029; commercial readiness activities ongoingOver 300 patients enrolled in darovasertib and crizotinib registrational 1L HLA-A2-negative MUM trial; targeting median PFS results by YE 2025 to enable potential accelerated approval filingSuccessful FDA Type D meeting completed to finalize darovasertib Ph3 registrational trial design and received U.S. FDA Breakthrough Therapy Designation in neoadjuvant UMTargeting three darovasertib program clinical data updates at medical conferences in 2025, including 1L MUM mOS results in >40 patients and neoadjuvant UM data in >90

      5/6/25 6:05:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors

      Targeting to evaluate IDE849 (SHR-4849) in SCLC, NETs, and other DLL3-upregulated solid tumors, and in combination with IDE161/PARG to potentially enhance durabilityTargeting to present clinical data of over 40 SCLC patients, including the dose escalation and expansion, from partner Hengrui at medical conference in Q3 2025SOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial to

      5/6/25 6:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events

      SOUTH SAN FRANCISCO, Calif., April 28, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events. Barclays Hosted: Peter Lawson's Catalyst & Key Debate Calls & Investor 1x1'sThursday, May 8th, 2025 at 11:00 AM ET Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Peter Lawson, D.Phil., Managing Director, Equity Research Analyst2025 RBC Capital Markets Global Healthcar

      4/28/25 6:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IDYA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stephens initiated coverage on IDEAYA Biosciences with a new price target

      Stephens initiated coverage of IDEAYA Biosciences with a rating of Overweight and set a new price target of $51.00

      11/18/24 8:39:33 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Biosciences downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded IDEAYA Biosciences from Outperform to Market Perform and set a new price target of $27.00

      11/5/24 7:22:44 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on IDEAYA Biosciences with a new price target

      UBS initiated coverage of IDEAYA Biosciences with a rating of Buy and set a new price target of $50.00

      10/24/24 6:22:17 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IDYA
    Leadership Updates

    Live Leadership Updates

    See more
    • IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer

      SOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the appointment of Joshua Bleharski, Ph.D. as Chief Financial Officer.  Dr. Bleharski joins IDEAYA from J.P. Morgan, where he spent nearly 17 years advising clients in the biopharma sector on capital markets transactions, corporate strategy and other investment banking services. IDEAYA anticipates that Dr. Bleharski will complete the transition into his new role by early May. 

      2/10/25 6:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer

      Brings over 20-year global commercialization experience in oncology with leading biopharmaceutical companies Gilead Sciences and Bristol Myers Squibb, including leadership of multiple commercial launches for products including Trodelvy® and Opdivo®SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the appointment of Stu Dorman as Chief Commercial Officer. Mr. Dorman has a track record of commercial success in numerous specialty disease areas with over 20 years of oncology and hematology experience.

      11/18/24 6:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel

      Over 25 years of legal experience with leading healthcare organizations, including GW Pharmaceuticals, Actelion Pharmaceuticals, Eisai, GSK, and the U.S. FDASOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that Douglas B. Snyder, joined the company as its Senior Vice President, General Counsel on September 18, 2024. "Doug brings a broad legal background in the healthcare field spanning biotechnology, pharm

      9/18/24 6:00:00 AM ET
      $IDYA
      $GWPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals

    $IDYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Beaupre Darrin

      4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)

      2/28/25 6:03:47 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Commercial Officer Dorman Stuart

      4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)

      2/28/25 6:02:27 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Ruiz Briseno Andres

      4 - IDEAYA Biosciences, Inc. (0001676725) (Issuer)

      2/28/25 6:02:04 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IDYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

      SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

      11/14/24 4:23:02 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

      SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

      11/14/24 3:13:37 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by IDEAYA Biosciences Inc.

      SC 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

      11/14/24 1:22:38 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IDYA
    Financials

    Live finance-specific insights

    See more
    • IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma

      Phase 2 company-sponsored and IST neoadjuvant uveal melanoma (UM) clinical data update in 49 evaluable patients, demonstrates ~49% of patients with >30% tumor shrinkage by product of diameters, and ~61% eye preservation rate for enucleation patientsTargeting to initiate Phase 3 randomized registrational trial in neoadjuvant UM following finalization of the clinical protocol with FDAClinical endpoints supportive of full approval based on FDA guidance: Eye preservation rate as the primary endpoint for enucleation patients. Time to vision loss as the primary endpoint for plaque brachytherapy patients. No detriment to Event-Free-Survival (EFS) in the treatment arms is a secondary endpointDiscuss

      9/23/24 6:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024

      SOUTH SAN FRANCISCO, Calif., Sept. 22, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that the company plans to issue a pre-market press release and conduct an investor webcast on Monday, September 23, 2024, at 8:00 a.m. ET to report interim Phase 2 data for darovasertib and provide a regulatory update from FDA Type C meeting in neoadjuvant uveal melanoma (UM). Darovasertib is a potent and selective protein kinase C (PKC) inhibitor being developed to broadly address primary and metastatic UM.

      9/22/24 9:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer

      ~39% Overall Response Rate (ORR): 1 CR and 6 PRs (2 awaiting confirmation) by RECIST 1.1 out of 18 evaluable MTAP-deletion urothelial and NSCLC patients~94% Disease Control Rate (DCR): 1 CR and 6 PRs and 10 SD by RECIST 1.1~78% of Patients with Tumor Shrinkage: 14 patients observed tumor shrinkage~81% ctDNA Molecular Response Rate (MRR): 13 of 16 patients with > 50% ctDNA reductionAE Profile: ~5.6% drug-related grade >3 AEs and no drug-related SAEs or discontinuations at 30 mg once-a-day expansion doseIDE397 expansion dose of 30 mg once-a-day achieved target drug coverage and plasma SAM pharmacodynamic reduction associated with preclinical tumor regressions~48k U.S. annual incidence of MTAP-

      7/8/24 6:00:00 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IDYA
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by IDEAYA Biosciences Inc.

      SCHEDULE 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject)

      5/14/25 12:26:18 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by IDEAYA Biosciences Inc.

      10-Q - IDEAYA Biosciences, Inc. (0001676725) (Filer)

      5/6/25 4:05:35 PM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IDEAYA Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer)

      5/6/25 6:05:15 AM ET
      $IDYA
      Biotechnology: Pharmaceutical Preparations
      Health Care